News & Updates

A confidence-based artificial intelligence (AI) biomarker demonstrates clinical utility in the diagnosis of liver cancer, according to a real-world study.

Hepatic steatosis may raise the risk of major adverse cardiovascular events through increased non-calcified plaque burden, according to a study.

A recent study describes the natural history of alcohol-associated liver disease (ALD) and the risks of outcomes based on the model for end-stage liver disease (MELD) score across the ALD spectrum.

Among patients with viral hepatitis-related cirrhosis who sustained non-bleeding decompensating events, the use of non-selective beta blockers is associated with lower mortality, as shown in a study.

In hepatitis B e antigen-negative (HBeAg) patients, the last antiviral agent used prior to end of therapy (EOT) appears predictive of the timing of clinical relapse, according to a study. An entecavir-switching strategy may prevent relapse and reduce hepatitis flare and its severity within 24 weeks after EOT.

Patients with primary sclerosing cholangitis (PSC) who received norucholic acid (NCA), with or without ursodeoxycholic acid (UDCA) background therapy, were more likely to achieve histological and biochemical improvements than those receiving placebo, according to the subgroup analysis of the NUC-5 trial presented at EASL 2026.

The prevalence and severity of coronary atherosclerosis are significantly higher among recipients of liver transplant than the general population, a study has shown.

Consumption of sugar-sweetened beverages may contribute to an increased risk of liver cancer, according to a meta-analysis.